Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Huoxuetongmai is a Traditional Chinese Medicine (TCM) formulation, commonly available in capsule or tablet form, designed to promote blood circulation and resolve blood stasis. It is frequently utilized in China for the treatment of cardiovascular and cerebrovascular diseases, including coronary heart disease, angina pectoris, and the sequelae of stroke. The formulation typically includes a combination of botanical extracts such as *Salvia miltiorrhiza* (Danshen), *Panax notoginseng* (Sanqi), and *Spatholobus suberectus* (Jixueteng). In clinical research, such as studies conducted by Jiaxing First Hospital, it is being evaluated for its efficacy in treating post-stroke symptoms like limb coldness, often in combination with surgical interventions like radiofrequency sympathetic nerve amputation. Its therapeutic effects are attributed to its ability to improve microcirculation, reduce blood viscosity, and exert anti-inflammatory and neuroprotective properties.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Huoxuetongmai.